Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ ICU admission -3% Improvement Relative Risk Respiratory failure 74% Oxygen therapy 20% Progression to dyspnea 70% Dyspnea 10% Recovery 20% primary Favipiravir  Chen et al.  LATE TREATMENT  RCT Is late treatment with favipiravir beneficial for COVID-19? RCT 236 patients in China Trial compares with arbidol, results vs. placebo may differ Lower progression (p=0.37) and lower oxygen therapy (p=0.42), not sig. c19early.org Chen et al., Frontiers in Pharmacology, Sep 2021 Favors favipiravir Favors arbidol

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial

Chen et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.683296
Sep 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Very late stage (9 days from symptom onset) RCT with 116 favipiravir patients and 120 arbidol patients in China, showing no significant difference in clinical recovery (relief of fever and cough, respiratory frequency ≤24 times/min, and oxygen saturation ≥98%), however the time to resolution of fever and cough was significantly lower with favipiravir. ChiCTR2000030254.
risk of ICU admission, 3.4% higher, RR 1.03, p = 1.00, treatment 2 of 116 (1.7%), control 2 of 120 (1.7%).
risk of respiratory failure, 74.1% lower, RR 0.26, p = 0.37, treatment 1 of 116 (0.9%), control 4 of 120 (3.3%), NNT 40.
risk of oxygen therapy, 19.5% lower, RR 0.80, p = 0.42, treatment 21 of 116 (18.1%), control 27 of 120 (22.5%), NNT 23.
risk of progression to dyspnea, 70.4% lower, RR 0.30, p = 0.03, treatment 4 of 116 (3.4%), control 14 of 120 (11.7%), NNT 12.
risk of dyspnea, 10.3% lower, RR 0.90, p = 0.84, treatment 13 of 116 (11.2%), control 15 of 120 (12.5%), NNT 77.
risk of no recovery, 19.7% lower, RR 0.80, p = 0.15, treatment 45 of 116 (38.8%), control 58 of 120 (48.3%), NNT 10, day 7, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chen et al., 2 Sep 2021, Randomized Controlled Trial, China, peer-reviewed, 14 authors, average treatment delay 9.0 days, this trial compares with another treatment - results may be better when compared to placebo.
This PaperFavipiravirAll
Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
Chang Chen, Yi Zhang, Jianying Huang, Ping Yin, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang, Bo Chen, Mengxin Lu, Yongwen Luo, Lingao Ju, Jingyi Zhang, Xinghuan Wang
Frontiers in Pharmacology, doi:10.3389/fphar.2021.683296
Background: In addition to supportive therapy, antiviral therapy is an effective treatment for coronavirus disease 2019 . Objective: To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients. Methods: We conducted a prospective, randomized, controlled, open-label multicenter trial involving adult patients with COVID-19. Enrolled patients with initial symptoms within 12 days were randomly assigned in a 1:1 ratio to receive conventional therapy plus Arbidol (200 mg*3/day) or favipiravir (1600 mg*2/first day followed by 600 mg*2/day) for 7 days. The primary outcome was the clinical recovery rate at day 7 of drug administration (relief for pyrexia and cough, respiratory frequency ≤24 times/min; oxygen saturation ≥98%). Latency to relief for pyrexia and cough and the rate of auxiliary oxygen therapy (AOT) or noninvasive mechanical ventilation (NMV)/mechanical ventilation (MV) were the secondary outcomes. Safety data were collected for 17 days. Results: A total of 240 enrolled COVID-19 patients underwent randomization; 120 patients were assigned to receive favipiravir (116 assessed), and 120 patients were assigned to receive Arbidol (120 assessed). The clinical recovery rate at day 7 of drug administration did not significantly differ between the favipiravir group (71/116) and Arbidol group (62/120) (p 0.1396, difference in recovery rate: 0.0954; 95% CI: −0.0305∼0.2213). Favipiravir contributed to relief for both pyrexia (difference: 1.70 days, p < 0.0001) and cough (difference: 1.75 days, p < 0.0001). No difference was observed in the
ETHICS STATEMENT The studies involving human participants were reviewed and approved by The study was approved by the Institutional Ethics Committee (No. 2020040). The patients/participants provided their written informed consent to participate in this study. AUTHOR CONTRIBUTIONS CC, YiZ, JH, and PY contributed equally to this paper. CC, JH, JW, and XW conceived and designed the study. CC, YiZ, JH, PY, ZC, JW, and YoZ contributed to patient recruitment, data collection, data analysis and data interpretation. CC, YiZ, JH, PY, SC, BC, ML, YL, and LJ wrote the first draft of the manuscript. CC, JH, and XW provided administrative, technical, or material support. JH and XW supervised the study. CC, YiZ, JH, JW, YoZ, BC, JZ, and XW contributed to the critical revision of the manuscript for important intellectual content. All authors reviewed and approved the final version of the manuscript. FUNDING This work was supported by the National Key Research and Development Program of China (2020YFC0844400). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. SUPPLEMENTARY MATERIAL The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.683296/ full#supplementary-material Conflict of Interest: Author YZ is employed by the company Euler..
References
Dong, Hu, Gao, Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19), Drug Discov. Ther, doi:10.5582/ddt.2020.01012
Du, Chen, Favipiravir: Pharmacokinetics and Concerns about Clinical Trials for 2019-nCoV Infection, Clin. Pharmacol. Ther, doi:10.1002/cpt.1844
Furuta, Takahashi, Fukuda, Kuno, Kamiyama et al., In Vitro and In Vivo Activities of Anti-influenza Virus Compound T-705, Antimicrob. Agents Chemother, doi:10.1128/aac.46.4.977-981.2002
Goldhill, Te, Velthuis, Fletcher, Langat et al., The Mechanism of Resistance to Favipiravir in Influenza, Proc. Natl. Acad. Sci. U S A, doi:10.1073/pnas.1811345115
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N. Engl. J. Med, doi:10.1056/NEJMoa2002032
Hulseberg, Fénéant, Szymańska-De Wijs, Kessler, Nelson et al., Arbidol and Other Low-Molecular-Weight Drugs that Inhibit Lassa and Ebola Viruses, J. Virol, doi:10.1128/JVI.02185-18
Leneva, Burtseva, Yatsyshina, Fedyakina, Kirillova et al., Virus Susceptibility and Clinical Effectiveness Frontiers in Pharmacology | www.frontiersin
Leneva, Falynskova, Makhmudova, Poromov, Yatsyshina et al., Umifenovir Susceptibility Monitoring and Characterization of Influenza Viruses Isolated during ARBITR Clinical Study, J. Med. Virol, doi:10.1002/jmv.25358
Li, Guan, Wu, Wang, Zhou et al., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia, N. Engl. J. Med, doi:10.1056/NEJMoa2001316
Mentre, Taburet, Guedj, Anglaret, Keita et al., Dose Regimen of Favipiravir for Ebola Virus Disease, Lancet Infect. Dis, doi:10.1016/S1473-3099(14)71047-3
Nojomi, Yassin, Keyvani, Makiani, Roham et al., Effect of Arbidol (Umifenovir) on COVID-19: a Randomized Controlled Trial, BMC Infect. Dis, doi:10.26442/00403660.2019.03.000127
Roser, Ritchie, Ortiz-Ospina, Coronavirus Disease (COVID-19)-Statistics and Research
Shi, Xiong, He, Deng, Li et al., Antiviral Activity of Arbidol against Influenza A Virus, Respiratory Syncytial Virus, Rhinovirus, coxsackie Virus and Adenovirus In Vitro and In Vivo, Arch. Virol, doi:10.1007/s00705-007-0974-5
Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Who, Coronavirus Disease
Xu, Chen, Yuan, Yi, Ding et al., Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study, doi:https://ssrn.com/abstract=3542148%20or%20doi:%2010.2139/ssrn.3542148
Zhang, Wang, Peng, Peng, Zhang et al., Potential of Arbidol for post-exposure Prophylaxis of COVID-19 Transmission: a Preliminary Report of a Retrospective Cohort Study, Curr. Med. Sci, doi:10.1007/s11596-020-2203-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit